Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 0 days to 12 years, inclusive:~   * (0 to 28 days);~  * (29 days to 23 months);~  * (2 to 5 years 11 months);~  * (6 to 12 years).~2. Subjects undergoing elective cardiac, abdominal, orthopedic, or transplant surgery.~3. Subjects with a clinical diagnosis of hypovolemia developed within 24 hours from the completion of surgery, as judged by the Investigator.~4. Admitted to ICU or acute care floor for post-operative recovery and care, in relatively stable condition.~5. Subject, parent or guardian agrees to comply with the requirements of the protocol.~6. Subject, parent or guardian has signed an informed consent form (ICF) and a child assent form if appropriate.~7. Subject, parent or guardian has signed the Health Insurance Portability and Accountability Act (HIPAA) authorization.~Exclusion Criteria:~1. Intra-operative blood loss \> 50 mL/kg.~2. Severe hypoalbuminemia with serum albumin levels \< 1g/dL.~3. Known intolerance or allergy to albumin and/or plasma proteins.~4. Preterm neonates, defined as neonates with a gestational age of \<37 weeks (this criteria would only affect the 0-28 days group).~5. Burn and trauma patients.~6. Renal surgery.~7. Subjects with acute CNS injury or trauma would be excluded from the study.~8. Chronic renal insufficiency or acute renal failure (creatinine \> 1.5 of normal value or based on age-appropriate renal function parameters), or a history of renal transplantation.~9. Subjects with hypernatremia, defined as a Na level of ≥ 155 mEq/L.~10. Severe congestive heart failure (CHF) using one of the following classification systems: Ross Heart Failure Classification, modified Ross Heart Failure Classification, or New York University Pediatric Heart Failure Index (NYU PHFI).~11. Any concurrent medical, surgical or psychiatric condition that may, in the Investigator's opinion, affect the subject's ability to meet the protocol requirements.~12. Subject has participated in another interventional clinical study within 30 days prior to study enrollment. Subjects who are participating in another observational study are not excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Kedbumin 25% (Type: EXPERIMENTAL): Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation.
- Normal Saline Solution (Type: PLACEBO_COMPARATOR): Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).